NervGen Pharma (NGENF) Price & Analysis

Compare

79 Followers

NGENF Stock Chart & Stats

$4.37

$0.00(0.00%)

At close: Jan 08 4:00 PM EST

$4.37

$0.00(0.00%)

Day’s Range― - ―

52-Week Range$1.50 - $5.10

Previous CloseN/A

Volume22.02K

Average Volume (3M)135.64K

Market Cap

$329.71M

Enterprise Value$231.86M

Total Cash (Recent Filing)$15.73M

Total Debt (Recent Filing)$57.71K

Price to Earnings (P/E)―

Beta0.48

Next Earnings

Apr 02, 2026

EPS Estimate

-0.04

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.04

Shares Outstanding78,365,974

10 Day Avg. Volume172,718

30 Day Avg. Volume135,636

Financial Highlights & Ratios

PEG Ratio1.67

Price to Book (P/B)82.04

Price to Sales (P/S)0.00

P/FCF Ratio-12.55

Enterprise Value/Market Cap0.70

Enterprise Value/RevenueN/A

Enterprise Value/Gross Profit-8.31K

Enterprise Value/Ebitda-8.78

Forecast

1Y Price Target

$7.70

Price Target Upside76.20% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering1

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

NervGen Pharma News

NervGen Pharma Files SEC Registration to Advance Strategic Growth

NervGen Pharma ( ($TSE:NGEN) ) has shared an update. NervGen Pharma has filed a Form F-10 registration statement...

2d ago

NervGen Pharma Proposes Amendment to Warrant Terms

The latest announcement is out from NervGen Pharma ( ($TSE:NGEN) ). NervGen Pharma announced its intention to amend...

7d ago

NervGen Pharma Advances NVG-291 for Spinal Cord Injury Treatment

NervGen Pharma ( ($TSE:NGEN) ) has shared an announcement. NervGen Pharma has reported significant advancements in its CONNECT...

25d ago

NervGen Pharma’s NVG-291 Shows Promising Results in Spinal Cord Injury Treatment

NervGen Pharma ( ($TSE:NGEN) ) has provided an announcement. NervGen Pharma announced expanded data from its CONNECT SCI...

25d ago

NervGen Pharma Secures $10M to Propel Nasdaq Listing and NVG-291 Development

An update from NervGen Pharma ( ($TSE:NGEN) ) is now available. NervGen Pharma has successfully closed a US$10...

30d ago

NervGen Pharma Secures $10 Million to Propel Nasdaq Listing and NVG-291 Development

An announcement from NervGen Pharma ( ($TSE:NGEN) ) is now available. NervGen Pharma has announced a US$10 million...

1M ago

NGENF Earnings this Week: How Will it Perform?

Nervgen Pharma Corp (NGENF) is scheduled to report 3rd quarter earnings on 11/13/2025. Regarding Q3 estimates, Wall Street...

1M ago

Nervgen Pharma’s NVG-291 Study: A Potential Breakthrough in Spinal Cord Injury Treatment

Nervgen Pharma Corp (($NGENF)) announced an update on their ongoing clinical study. Nervgen Pharma Corp is conducting an...

2M ago

NGENF

NervGen Pharma Reports Breakthrough in Spinal Cord Injury Treatment

NervGen Pharma ( ($TSE:NGEN) ) just unveiled an update. NervGen Pharma announced groundbreaking results from its Phase 1b/2a...

4M ago

NervGen Pharma’s NVG-291-R Shows Promising Preclinical Results in Nerve Repair

NervGen Pharma ( ($TSE:NGEN) ) has issued an announcement. NervGen Pharma announced positive preclinical results for its drug...

4M ago

NervGen Pharma price target raised to C$6 from C$4.50 at Raymond James

Raymond James analyst Michael Freeman raised the firm’s price target on NervGen Pharma (NGENF) to C$6 from C$4.50...

6M ago

NervGen Pharma price target raised to C$5 from C$4.50 at Stifel

Stifel raised the firm’s price target on NervGen Pharma (NGENF) to C$5 from C$4.50 and keeps a Buy...

6M ago

NervGen reports topline data from chronic cohort of Phase 1b/2a trial of NVG-291

NervGen Pharma (NGENF) announced topline results from the chronic cohort of its Phase 1b/2a clinical trial evaluating its...

7M ago

NervGen Pharma price target raised to C$4.50 from C$3 at Raymond James

Raymond James analyst Michael Freeman raised the firm’s price target on NervGen Pharma (NGENF) to C$4.50 from C$3...

11M ago

NGENF FAQ

What was NervGen Pharma’s price range in the past 12 months?

NervGen Pharma lowest stock price was $1.50 and its highest was $5.10 in the past 12 months.

What is NervGen Pharma’s market cap?

NervGen Pharma’s market cap is $329.71M.

When is NervGen Pharma’s upcoming earnings report date?

NervGen Pharma’s upcoming earnings report date is Apr 02, 2026 which is in 104 days.

How were NervGen Pharma’s earnings last quarter?

NervGen Pharma released its earnings results on Nov 24, 2025. The company reported -$0.043 earnings per share for the quarter, beating the consensus estimate of -$0.062 by $0.018.

Is NervGen Pharma overvalued?

According to Wall Street analysts NervGen Pharma’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does NervGen Pharma pay dividends?

NervGen Pharma does not currently pay dividends.

What is NervGen Pharma’s EPS estimate?

NervGen Pharma’s EPS estimate is -0.04.

How many shares outstanding does NervGen Pharma have?

NervGen Pharma has 78,365,974 shares outstanding.

What happened to NervGen Pharma’s price movement after its last earnings report?

NervGen Pharma reported an EPS of -$0.043 in its last earnings report, beating expectations of -$0.062. Following the earnings report the stock price went up 10.915%.

Which hedge fund is a major shareholder of NervGen Pharma?

Currently, no hedge funds are holding shares in NGENF

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

NervGen Pharma Stock Smart Score

Outperform

Fundamentals

Return on Equity

-457.00%

Trailing 12-Months

Asset Growth

-39.15%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

NervGen Pharma

NervGen Pharma Corp., together with its subsidiaries, engages in the discovery, development, and commercialization of pharmaceutical treatments for medical conditions related to nervous system damage. Its lead product candidate is NVG-291 that is in phase 1 clinical trial for the treatment of spinal cord injuries (SCI), multiple sclerosis, and Alzheimer's disease. The company has a licensing agreement with Case Western Reserve University to research, develop, and commercialize a patented technology with therapeutic potential for SCI and other conditions associated with nerve damage. NervGen Pharma Corp. was incorporated in 2017 and is based in Vancouver, Canada.

NervGen Pharma (NGENF) Earnings & Revenues

Historic Earnings Reports

NGENF Stock 12 Month Forecast

Average Price Target

$7.70

▲(76.20% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"$0","2":"$2","4":"$4","6":"$6","8":"$8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":7.7,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$7.70</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":7.7,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$7.70</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":7.7,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$7.70</span>\n  </div></div>","useHTML":true}}],"tickPositions":[0,2,4,6,8],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jul<br/>2024","6":"Dec<br/>2024","9":"Jun<br/>2025","12":"Nov<br/>2025","25":"Nov<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.48,2.8815384615384616,3.2830769230769232,3.684615384615385,4.086153846153846,4.487692307692308,4.889230769230769,5.2907692307692304,5.6923076923076925,6.093846153846155,6.495384615384616,6.896923076923077,7.298461538461538,{"y":7.7,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.48,2.8815384615384616,3.2830769230769232,3.684615384615385,4.086153846153846,4.487692307692308,4.889230769230769,5.2907692307692304,5.6923076923076925,6.093846153846155,6.495384615384616,6.896923076923077,7.298461538461538,{"y":7.7,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.48,2.8815384615384616,3.2830769230769232,3.684615384615385,4.086153846153846,4.487692307692308,4.889230769230769,5.2907692307692304,5.6923076923076925,6.093846153846155,6.495384615384616,6.896923076923077,7.298461538461538,{"y":7.7,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":1.44,"date":1661990400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.48,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.43,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.16,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.1,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.83,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.06,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.18,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.09,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.58,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.49,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.46,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.48,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >